Eddy S. Yang is a Professor, Vice Chairman for Translational Science, Deputy Director and Associate Director for Precision Oncology, Hugh Kaul Precision Medicine Institute, Program co-Leader Experimental Therapeutics, UAB Comprehensive Cancer Center, ROAR Southeast Cancer Foundation Endowed Chair.
His research interests involve the targeting of DNA repair pathways to enhance the therapeutic ratio. We aim to discover novel strategies to augment DNA repair pathways to specifically protect normal cells from DNA damage while reducing DNA repair capacity to convert cancer cells to become more susceptible to DNA damaging agents.
Eddy S. Yang completed his B.A.-Biology, Johns Hopkins University, 1996, Ph.D.-University of Miami School of Medicine, Miami, FL 2003, M.D.-University of Miami School of Medicine, Miami, FL 2005, Internship-Mount Sinai Medical Center, Miami Beach, FL 2006, Residency-Vanderbilt University School of Medicine, Nashville, TN 2010 and Brachytherapy Fellowship - Seattle Prostate Institute 2010. He had received many awards and honors.
Prof. Dr. Kadriye Benkli has completed her Ph.D. from Health Science Institute in Anadolu University, Eskisehir, Turkey and postdoctoral studies from Leiden University, Gorleous Lab., Leiden, The Netherlands. Her research interests include the regulation of cancer. Currently, she is a Head of the Pharmaceutical Chemistry Department, Faculty of Pharmacy, Girne American University.
Lynnette Ferguson completed her D.Phil. (Oxon), the equivalent of a Ph.D., from Oxford University in the UK, followed by a Post-doctoral Fellowship at the School of Biological Sciences at The University of Auckland, New Zealand. Her research interests include the causes of cancer, especially those involving the diet. Currently, she is an Emeritus Professor in the School of Medical Sciences and The Auckland Cancer Society Research Centre, continuing to interact with students and other staff at the Medical School.
Leroy J. Lowe
President and Cofounder of Getting to Know Cancer (NGO), Canada
Leroy J. Lowe is the President and Cofounder of Getting to Know Cancer, a Canadian Non-profit that is focused on the advancement of cancer research. His Ph.D. is from Lancaster University in the UK and he is the key architect of the Halifax Project (2011-2015), a global initiative that involved more than 350 cancer researchers in 31 countries. Dr. Lowe is currently focused on the Broadspec Clinical Trials, a multi-institution case-series that will encompass prophylactic trials for myelodysplastic syndrome patients who are at high risk of developing acute myeloid leukemia and therapeutic trials for patients with advanced-stage ovarian cancer, pancreatic ductal adenocarcinoma, or glioblastoma multiforme.
Nagi B. Kumar
University of South Florida College of Medicine, USA
Dr. Nagi Kumar, Ph.D., is the Director of Cancer Chemoprevention, Senior Member, Cancer Epidemiology, Genitourinary Oncology and Breast Programs at the Moffitt Cancer Center, and Professor, Department of Oncologic Sciences, University of South Florida College of Medicine in Tampa, Florida. By forging collaborations with investigators in basic, population and clinical sciences nationally and internationally, Dr. Kumar has developed and led a focused research initiative at the Moffitt Cancer Center to accelerate agent development, utilizing a systematic, broad-spectrum approach that involves combining multiple, standardized, botanicals, biologics and repurposed agents that can: (a) enhance bioavailability; (b) produce robust and synergistic targeting of relevant and multiple pathways in target tissue; (c) address the underlying biology of carcinogenesis; (d) with minimum toxicity in (e) exceptionally high-risk populations. Funded by the National Cancer Institute, this endeavor has resulted in over 100 national and international peer-reviewed publications and over 200 national and international presentations.
Dr. Huang is a tenured Associate Professor in the Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota. She is a member of American Association for Cancer Research (AACR), American Society of Human Genetics (ASHG), and American Society of Clinical Pharmacology and Therapeutics (ASCPT). She is a senior editor for Genomics Discovery. She also serves on the editorial board of Genomics, Proteomics and Bioinformatics; Chemotherapy; and Journal of Blood Disorders & Transfusion. She published more than 70 original research papers many of which are in high caliber journals, e.g., Nature, Nature Medicine, PNAS, Blood, Cancer Research, Genome Biology and American Journal of Human Genetics. She is a grant awardee for NIH NCI, NIGMS, and many different foundations.
Liu Qiuzhen is a Doctor, professor, doctoral supervisor. His research interests include tumor immune escape and tumor metabolism. From 2010 to 2013, he worked and studied at the National Institutes of Health for three years. The research focuses on the molecular mechanism of melanoma immune escape. Mainly published article (Melanoma NOS1 expression promotes dysfunctional IFN signaling. Journal of clinical investigation. JCI. 2014.5). Obtained the project leader of "Study on the Molecular Mechanism of NOS1 Inhibiting the Immune Escape of Melanoma Caused by IFNa / JAK / STAT Pathway" by the Natural Science Foundation of China. Leader of the Guangdong Provincial Planning Project “Research on Targeted Therapy of Cancer Stem Cells”. Research interests are Molecular Mechanisms of NOS Regulating Metabolism and Immunity.
Dr. Luigia Carapezza is currently working as a Psycho-oncologist in UOC Medical Oncology - ARNAS Garibaldi Hospitality Center, Italy. She has inspired by the guidelines of the most authoritative Scientific Societies in the sector. Experience gained in about nine years of activity in the hospital environment. The main professional activities dedicated to cancer patients are listed below: Screening of psychological distress. Psychological interventions aimed at reducing psychosocial distress. Management of psychological problems associated with the disease. Detect and respond to patients' psychosocial needs. Interventions dedicated to cancer sick parents to facilitate the sharing of the diagnosis in the family and with minor children. Psychoeducation interventions dedicated to the prevention of depressed mood. Psychoeducation interventions on emotional regulation. Psychoeducation interventions aimed at promoting the quality of life during cancer treatments. Relaxation training to reduce anxiety and/or to promote the sleep-wake cycle. Implementation of mindfulness techniques to promote the quality of life in the "here and now". Psychological support dedicated to family members and caregivers. Psychological assistance during painful / invasive procedures. Creation of projects for the promotion of psychophysical well-being. Research.